Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex Granted Summary Judgment In US Pennsaid 2% Infringement Suit

Delaware District Court Case Involved Licensing Deal Signed In 2013

Executive Summary

Apotex has decisively overcome Horizon’s patent infringement suit stemming from its launch of a generic version of the originator’s Pennsaid 2%.

You may also be interested in...



US Appeals Court Refuses To Review Pennsaid 2%

Unsatisfied with a US Court of Appeals upholding a ruling in favor of Teva's Actavis that several Pennsaid 2% patents were invalid, Horizon Therapeutics sought to have the case reheard en banc. However, the request has been refused.

HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal

Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.

Five Big Legal Stories From 2022

Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel